Women have a higher mortality rate in ST-segment elevation acute myocardial infarction 

Original title: Is the difference in outcome between men and women treated by primary percutaneous coronary intervention age dependent?: Gender difference in STMI stratified on age Reference: Amber M Otten et, al.European Heart Journal Acute Cardiovascular Care January 31:1-8

Numerous publications have shown that women have worse outcomes than men in chronic ischemic heart disease but their evolution in the context of ST segment elevation acute myocardial infarction, (STEMI), has not been fully studied.

6,746 patients admitted with STEMI were analyzed between 1998 and 2008, dividing them into four groups: women under 65 years (n = 708), men younger than 65 years (n = 3,006), women older than 65 years (n = 1,045) and men older than 65 years (n = 1,985). 

Women had more time from the onset of symptoms to hospital admission as opposed to door-to-balloon time that was equal in both sexes. At initial angiography less obstructive disease was found, a higher TIMI 3 flow and a reduced release of CK in women younger than 65 years versus men in the same age group. In the larger group of over 65 years there was no difference between the sexes in multi-vessel disease and TIMI flow 3. The result after angioplasty in terms of TIMI and Blush was similar in both sexes. 

Overall mortality at thirty days and one year was greater in women. In the group under 65 years women had a higher mortality rate at both thirty days and one year. For those over 65 years the mortality rate was higher only after thirty days.

Conclusion: 

The difference in mortality between men and women admitted with an acute ST segment elevation was age dependent. Young women had less frequent coronary obstruction and TIMI 3 flow before angioplasty, suggesting a lower risk, yet their prognosis was worse compared with men of the same age.

Comment: 

The delay in consulting a hospital from the onset of symptoms may explain the impact on mortality in women. 

Courtesy Dr Carlos Fava.
Interventional Cardiologist.
Favaloro Foundation. 

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...